Compounded vs Brand-Name GLP-1: What's the Difference?

If you've researched GLP-1 weight loss at all, you've seen two price tiers: brand-name Wegovy® or Zepbound® at ~$1,100–1,400 per month, and "compounded" alternatives through telehealth starting under $200. The 7–10x price gap raises a fair question — what are compounded medications, exactly, and how do they differ from FDA-approved products? This guide walks through the legal, regulatory, and practical differences. Compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality.

Quick comparison

What "compounded" actually means

A compounded medication is prepared for a specific patient by a licensed pharmacist. This is an old practice — pharmacists have been compounding for centuries. A pharmacist might combine two medications for a patient allergic to an inactive ingredient, prepare a liquid version of a pill for a child who can't swallow, or prepare a non-standard dose strength for a patient whose clinical needs aren't met by a commercially available product.

Under federal law (the Drug Quality and Security Act, 2013), compounding falls into two categories:

503A compounding pharmacies prepare medications per individual prescription. They're regulated by state pharmacy boards and must follow USP <797> standards for sterile compounding.

503B outsourcing facilities prepare medications in larger batches, have stricter FDA oversight, and can ship to multiple prescribers. These are the facilities most telehealth GLP-1 programs use.

Both are legal, both are regulated, both have compliance requirements for purity testing, sterility, and sourcing.

When can compounding pharmacies prepare these medications?

Under federal law, compounding pharmacies generally cannot prepare a copy of a commercially available FDA-approved drug. Compounding is permitted under FDCA §503A(b)(1)(C) when a licensed prescriber determines, on a patient-specific basis, that a compounded preparation produces a clinically significant difference for that patient — for example, an intolerance to an inactive ingredient in the FDA-approved product, a need for a non-standard dose strength not commercially available, or another documented clinical reason the FDA-approved product is not appropriate.

The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Compounded GLP-1 prescriptions issued after those dates are not based on shortage status; each prescription is supported by a documented patient-specific clinical-difference rationale under §503A(b)(1)(C). Pricing alone is not a sufficient basis for compounding under FDA guidance.

How do compounded preparations compare to FDA-approved products?

Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. The FDA has stated that companies cannot claim non-FDA-approved compounded products are generic versions of, or the same as, FDA-approved drugs. Compounded preparations have not been evaluated by the FDA for safety, efficacy, or quality.

What differs in practice between an FDA-approved product and a compounded preparation:

• Concentration and dose presentation — a Wegovy® pen delivers a specific volume per click; a compounded vial requires drawing up a specific volume with a syringe. Your provider tells you exactly how much to draw
• Inactive ingredients — preservatives, buffers, and carriers vary. Brand-name uses a specific FDA-approved formulation; compounded versions may vary by pharmacy
• Testing protocols — brand-name goes through batch release testing at FDA-inspected manufacturing sites. Compounded versions are tested to USP standards and state pharmacy board requirements, which are rigorous but different
• Packaging and stability data — brand-name has extensive stability data behind specific storage conditions; compounded versions typically have shorter expiration windows

What's actually different in practice

Injection experience

Brand-name Wegovy® and Zepbound® come as pre-filled injection pens — you twist the dose, inject, done. Very user-friendly.

Compounded semaglutide typically comes as a vial with a separate syringe. You draw up the correct volume, then inject. Slightly more steps but takes 30 seconds with practice. Some compounding pharmacies now offer pre-filled pens.

Dose flexibility

Pens have fixed dose increments — a Wegovy® pen goes 0.25, 0.5, 1.0, 1.7, 2.4 mg per injection and you can't easily deviate.

Compounded vials let a provider prescribe non-standard doses — say, 0.75 mg when you're having trouble at 1.0 mg but fine at 0.5 mg. This flexibility can be valuable if you're sensitive to titration.

Reliability of supply

Brand-name is subject to pharmacy stocking and insurance prior auth delays. Even when covered, patients routinely wait days or weeks for refills.

Compounded via telehealth is typically shipped directly to you on a predictable monthly cadence. No pharmacy pickup, no prior auth wrestling.

Long-term safety data

Brand-name Wegovy® has been used by millions of patients since FDA approval in 2021. There is extensive post-market safety data on the FDA-approved product.

Compounded preparations have not been evaluated by the FDA and do not have the long-term post-market data that FDA-approved products have accumulated. Patients should discuss the relative evidence base with their prescribing provider.

Common misconceptions

"Compounded means generic." No — these are legally and regulatorily distinct. Generics are FDA-approved copies of brand drugs (there are no generic GLP-1s yet). Compounded medications are prepared per prescription by licensed pharmacies under compounding regulations.

"Compounded isn't regulated." It is — by state boards of pharmacy, the FDA's compounding rules, and USP standards. It's regulated differently than brand-name drugs, which go through FDA new drug approval.

"Compounded is lower quality." Not inherently. A reputable 503B outsourcing facility follows strict sterility, potency, and testing protocols. Some compounded products are better than others depending on the facility. The variability is real but doesn't mean compounded is categorically worse.

"The FDA says compounded GLP-1s are unsafe." The FDA has issued warnings about specific risks — unapproved salt forms like semaglutide sodium that don't match the FDA-approved base, and pharmacies operating outside compounding rules. These warnings are legitimate. They don't mean all compounded GLP-1s are unsafe — they mean patients should use reputable programs that source from 503B facilities using the correct base form.

"Lower price means lower quality." Price differences reflect the underlying business and regulatory pathways: brand-name drugs recover R&D, FDA approval, and post-market study costs through unit pricing, while compounded preparations are dispensed against patient-specific prescriptions through a different regulatory framework. A different price does not, on its own, indicate clinical equivalence in either direction — and the FDA has been explicit that price cannot be cited as a basis for compounding in place of an available FDA-approved product.

How to evaluate a compounded telehealth program

Not all compounded GLP-1 programs are equal. When evaluating one, ask:

1. What pharmacy do you use? Reputable programs partner with specific 503B outsourcing facilities or high-quality 503A pharmacies. They should be able to name the pharmacy and its licensing.
2. What form of semaglutide do you use? The answer should be "semaglutide" or "semaglutide base." Be cautious of "semaglutide sodium" or "semaglutide acetate" — these are different salt forms not used in the FDA-approved product, and the FDA has flagged them specifically.
3. Are your providers licensed in my state? Required for legitimate telehealth prescribing. Should be a straightforward yes.
4. What's the clinical-difference rationale used for prescribing? With both shortages now resolved, every compounded GLP-1 prescription should be supported by a documented patient-specific reason under FDCA §503A(b)(1)(C) — an intolerance to the FDA-approved formulation, a non-standard dose, or another clinical reason. If a program can't articulate this, that's a red flag.
5. Can I message a provider between scheduled visits? Especially during titration, provider accessibility matters more than most other features.

Brand vs compounded: which is right for you?

Choose brand-name if:

• You have insurance that covers Wegovy® or Zepbound® (copay often $25–$150)
• You want the longest post-market safety track record
• You strongly prefer the pen form factor
• Cost isn't a primary constraint

Choose compounded via telehealth if:

• You don't have insurance coverage for weight-loss GLP-1s
• Brand-name cash pricing is out of budget (most people)
• You're comfortable with vial + syringe injection
• You want predictable monthly delivery
• You understand the regulatory tradeoffs

Either works if:

• You have a provider you trust to guide the choice
• You're willing to switch if one stops working or becomes unavailable

For a deeper look at pricing specifically, see how much semaglutide costs without insurance. For the clinical differences between the two major GLP-1 options, see semaglutide vs tirzepatide.

Frequently asked questions

Will compounded semaglutide produce the same weight loss as Wegovy®? Compounded preparations have not been clinically evaluated, and the published clinical trial results for FDA-approved Wegovy® and Zepbound® were observed with those FDA-approved products and have not been clinically established for compounded medications. Outcomes for compounded products are not guaranteed and cannot be predicted from brand-name trial data. Discuss expectations with your prescribing provider, who can document a clinical-difference rationale and monitor your individual response.

What are the risks specific to compounded preparations? Because compounded preparations are not FDA-approved, they have not been subject to the FDA's safety, efficacy, and quality review. The FDA has separately warned about specific risks tied to non-reputable sources — pharmacies operating outside compounding regulations, unapproved salt forms (e.g., semaglutide sodium or semaglutide acetate, which are not the form used in FDA-approved products), and products sold outside a licensed provider relationship. Pallas works only with US-licensed 503A and 503B compounding pharmacies and does not work with semaglutide sodium or semaglutide acetate.

Can I switch from compounded to brand-name later? Yes, routinely. Your provider can transition you to a brand-name prescription. Your current dose translates directly. The only adjustment is billing and pharmacy routing.

Does my HSA/FSA cover compounded medications? Typically yes — they're prescription healthcare expenses. Most telehealth platforms provide receipts suitable for HSA/FSA reimbursement. Check with your specific administrator.

Has the GLP-1 shortage ended? Yes. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Compounded GLP-1 prescriptions issued after those dates are not based on shortage status — they require a documented patient-specific clinical-difference rationale under FDCA §503A(b)(1)(C). If your prescriber determines a compounded preparation is no longer clinically appropriate for you, they can transition you to an FDA-approved product.

Is it legal to buy compounded GLP-1 online? Yes, when prescribed by a licensed provider and dispensed by a licensed pharmacy in a state where telehealth prescribing is legal for this category. Pallas (and reputable competitors) operate within these boundaries. Online sellers offering semaglutide or tirzepatide as research chemicals — without a prescription, without a licensed-provider relationship, and outside the compounding-pharmacy framework — are not legitimate and are operating illegally.

Bottom line: Brand-name Wegovy® and Zepbound® are FDA-approved products with published clinical trial data and an established post-market safety record. Compounded preparations are not FDA-approved, are not generic versions, and have not been clinically evaluated; they are dispensed by US-licensed compounding pharmacies under §503A(b)(1)(C) when a prescriber documents a patient-specific clinical-difference rationale. The two products are regulated through different frameworks and are not interchangeable. The right path depends on your insurance coverage, your provider's clinical assessment, and your tolerance for the regulatory and evidentiary differences described above.